The binding of GLP-1 (or semaglutide) to GLP-1 receptors activates several biological responses: Increased insulin secretion after food intake, which improves blood glucose levels Reduced glucagon secretion, which limits glucose in the blood and helps reduce spikes in blood sugar Slowed emptying of the stomach, which helps people feel less hungry during the day Suppressed appetite, which again helps with feelings of satiety All of these factors promote sustained food (and therefore calorie) reduction, supporting weight loss with time
Lillys Data Suggests Yes According to American Diabetes Association, approximately 1.2 million Americans are diagnosed with diabetes every year making it the 8th leading cause of death nationwide
Direct vs Indirect Risk: An Important Difference A common misunderstanding surrounding Wegovy kidney stones concerns is that the medication directly causes kidney stones or damages the kidneys
Nanoparticle-mediated delivery of inhaled immunotherapeutics for treating lung metastasis
Oral BPC-157 works for gut health applications but delivers lower bioavailability for joint and tendon targets
In the latest episode of the Annals Consult Guys, the guys are joined by Douglas Pfeil, MD to provide advice on the management of glucagon-like peptide-1 (#GLP1) receptor agonist therapy in a patient undergoing surgery for an acute hip fracture